Skip to main content
Menu

Posts tagged with "Clinical Trials"

  • Cancer

    An Unexpected Halt in Multiple Myeloma for Venetoclax

      Venetoclax (ABT-199) is an unusual drug. But now there’s some unusually bad (and unexpected) news about it. That’s the structure at right, and medicinal chemists will understand immediately why it’s a bit of an outlier. With a molecular weight of 868, that structure just keeps on going, with a somefeatures that you donR… Read More
  • Business and Markets

    Zafgen: Will There Be a Third Act?

    A few years ago on this blog, I wrote several times about a small company called Zafgen and their unusual epoxide-based chemical matter (beloranib) that was in development for the rare Prader-Willi syndrome. That’s a genetic disorder that includes, among many other problems, constant hunger (with the complications that you’d expect fro… Read More
  • Business and Markets

    The Clinic Giveth And Most Definitely Taketh Away

    There have been some pretty dramatic clinical trial results coming out recently, and unfortunately drama is a variable that can take either a positive or a negative sign in front of it. On the plus side, MacroGenix, a company that not many people had been paying attention to, announced results of a head-to-head trial of… Read More
  • Biological News

    Precision Medicine Real Soon Now

    Here’s a strongly opinionated look at where the “precision medicine” field is these days, and I think that this is just the sort of article that the field (and the journalists covering it) need to see, whether you agree with it or not: In 1999 Francis Collins published a foundational document of precision medicine entitled… Read More
  • Alzheimer's Disease

    Another Alzheimer’s Antibody Fails. There Will Be More.

    To what should be absolutely no human being’s surprise, another amyloid-antibody trial has failed. Roche announced today that the Phase III work (two 750-patient trials) on crenezumab after an interim analysis showed a strong chance of futility. They’re still going on with a study in familial early-onset disease in Colombia, and they ha… Read More
  • Alzheimer's Disease

    A New Infectious Mechanism for Alzheimer’s?

    We have another entry in the “Is Alzheimer’s caused by infectious disease?” drawing, and it’s a good one. A large multicenter team reports that Porphyromonas gingivalis, which is the key pathogen in gingivitis (gum disease) may be the actual causative agent in Alzheimer’s, which is a bold claim indeed. But they have… Read More
  • Clinical Trials

    Artemisia Comes Through Again

    Here’s an unusual twist for you. Many readers will be familiar – to their regret, most likely – with the story of T*ring Pharmaceuticals (name redacted slightly in order to not defame a great scientist whose name was tacked on to this outfit for no reason other than advertising). Their first idea was to go… Read More
  • Clinical Trials

    Making Excuses, the Modern Way

    This one will be good for a wry smile, a roll of the eyes, or perhaps a knowing shiver. The British Medical Journal has published a “Key opinion leaders’ guide to spinning a disappointing clinical trial result”, and many are the times that such a handbook is needed, unfortunately: When key opinion leaders are asked… Read More
  • Business and Markets

    Worse Than Useless

    Time for another look at AbbVie’s work on Rova-T (an antibody-drug conjugate targeting the tumor antigen DLL3), and for some hard thoughts about what drug development is really like. The last time I wrote about this program, things didn’t look good. Now they look even worse. A Phase III trial of the drug has been… Read More
  • Cancer

    PI3K Inhibitors: You’re Doing It Wrong

    Now here’s an interesting connection between cancer and metabolism, with what look to be direct implications for therapy. A large research team (mostly working out of Weill Cornell) reports some new and important details about PI3K inhibitors, a class of kinase inhibitors that has seen a very large amount of development work indeed. I’v… Read More
...234...